CA2830012C - New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids - Google Patents

New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids Download PDF

Info

Publication number
CA2830012C
CA2830012C CA2830012A CA2830012A CA2830012C CA 2830012 C CA2830012 C CA 2830012C CA 2830012 A CA2830012 A CA 2830012A CA 2830012 A CA2830012 A CA 2830012A CA 2830012 C CA2830012 C CA 2830012C
Authority
CA
Canada
Prior art keywords
group
xaa
seq
acid
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2830012A
Other languages
English (en)
French (fr)
Other versions
CA2830012A1 (en
Inventor
Francoise Baleux
Hugues Lortat-Jacob
David Bonnaffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université Paris-Sud
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique
Université Paris-Sud
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Université Paris-Sud, Institut Pasteur filed Critical Centre National de la Recherche Scientifique
Publication of CA2830012A1 publication Critical patent/CA2830012A1/en
Application granted granted Critical
Publication of CA2830012C publication Critical patent/CA2830012C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2830012A 2011-03-18 2012-03-16 New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids Expired - Fee Related CA2830012C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305309A EP2505210A1 (en) 2011-03-18 2011-03-18 Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanionic polypeptide for the treatment of aids
EP11305309.4 2011-03-18
US201261590992P 2012-01-26 2012-01-26
US61/590,992 2012-01-26
PCT/EP2012/054674 WO2012126833A1 (en) 2011-03-18 2012-03-16 New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids

Publications (2)

Publication Number Publication Date
CA2830012A1 CA2830012A1 (en) 2012-09-27
CA2830012C true CA2830012C (en) 2018-11-06

Family

ID=44118425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2830012A Expired - Fee Related CA2830012C (en) 2011-03-18 2012-03-16 New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids

Country Status (9)

Country Link
US (1) US9078928B2 (cg-RX-API-DMAC10.html)
EP (2) EP2505210A1 (cg-RX-API-DMAC10.html)
JP (1) JP6046060B2 (cg-RX-API-DMAC10.html)
CN (1) CN103429269B (cg-RX-API-DMAC10.html)
BR (1) BR112013023859A2 (cg-RX-API-DMAC10.html)
CA (1) CA2830012C (cg-RX-API-DMAC10.html)
MX (1) MX336727B (cg-RX-API-DMAC10.html)
WO (1) WO2012126833A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201306956B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3220957B1 (en) 2014-10-24 2018-11-07 Institut Pasteur Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to an anionic polypeptide for the treatment of aids
WO2017184564A1 (en) 2016-04-18 2017-10-26 Icagen, Inc. Sensors and sensor arrays for detection of analytes
WO2018140590A1 (en) * 2017-01-25 2018-08-02 Massachusetts Institute Of Technology Seft-labeling miniproteins and conjugates comprising them
CN109081789B (zh) * 2017-06-13 2021-01-01 首都医科大学 氨基正己酰氨基甲环酰氨基正己酰脂肪氨基酸，其合成，活性和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002338600A (ja) * 2001-05-17 2002-11-27 Japan Science & Technology Corp Ｈｉｖ−１の感染を抑制するポリペプチド
RU2270690C1 (ru) * 2004-06-11 2006-02-27 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") Комплексное анти-вич соединение
FR2904627B1 (fr) 2006-08-04 2008-11-07 Pasteur Institut Nouveaux peptides actives, purifies et isoles, derives du recepteur cd4 (mini-cd4) et leur procece de preparation
EP2087911A1 (en) 2008-02-06 2009-08-12 Institut Pasteur Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS

Also Published As

Publication number Publication date
EP2505210A1 (en) 2012-10-03
ZA201306956B (en) 2014-05-28
CA2830012A1 (en) 2012-09-27
MX336727B (es) 2016-01-27
US9078928B2 (en) 2015-07-14
MX2013010688A (es) 2014-03-27
CN103429269B (zh) 2016-05-11
EP2686019B1 (en) 2017-03-01
EP2686019A1 (en) 2014-01-22
JP2014509604A (ja) 2014-04-21
WO2012126833A1 (en) 2012-09-27
JP6046060B2 (ja) 2016-12-14
BR112013023859A2 (pt) 2018-09-25
US20140107043A1 (en) 2014-04-17
CN103429269A (zh) 2013-12-04

Similar Documents

Publication Publication Date Title
BRPI0707920A2 (pt) peptìdeo monomérico, peptìdeo multimérico o compreendendo, seu uso, peptìdeo dimérico, fusão e composição farmacêutica compreendendo o mesmo, bem como métodos de detecção de fcrn in vitro, sinterização de um dìmero de peptìdeo e para purificação de fcrn
US20240366775A1 (en) Human transferrin receptor binding antibody-peptide conjugate
EP2686019B1 (en) Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids
CA3210657A1 (en) Glucagon-like peptide-1 receptor antagonists
ES2367400T3 (es) Péptidos derivados del receptor cd4 y su procedimiento de preparación.
JP6647207B2 (ja) ヘマグルチニン結合ペプチド
US10738083B2 (en) Influenza virus neutralizing peptidomimetic compounds
EP3220957B1 (en) Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to an anionic polypeptide for the treatment of aids
CN110234337A (zh) 中和流感病毒的化合物
CA2065029A1 (en) Therapeutic compositions; methods for treatment of hiv infections
US20170360879A1 (en) Novel Cyclic Peptides and Methods Using Same
EA039991B1 (ru) Соединения-пептидомиметики, нейтрализующие вирус гриппа

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161130

MKLA Lapsed

Effective date: 20210316